{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:28:42Z","timestamp":1785900522375,"version":"3.56.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007835","name":"Wenzhou Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007835","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bcp.2025.116854","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T02:48:59Z","timestamp":1741142939000},"page":"116854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Inhibitory effects of nimodipine, nitrendipine and felodipine on tamoxifen metabolism and molecular docking"],"prefix":"10.1016","volume":"236","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5017-5515","authenticated-orcid":false,"given":"Xiaohai","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengsheng","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheli","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-ai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2025.116854_b0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12916-020-01797-2","article-title":"Breast cancer risk factors and their effects on survival: a Mendelian randomisation study","volume":"18","author":"Escala-Garcia","year":"2020","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.116854_b0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/CM9.0000000000001814","article-title":"Global and regional trends in incidence and mortality of female breast cancer and associated factors at national level in 2000 to 2019","volume":"135","author":"Luo","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.bcp.2025.116854_b0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast (edinburgh, Scotland)"},{"key":"10.1016\/j.bcp.2025.116854_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102339","article-title":"Global challenges and policy solutions in breast cancer control","volume":"104","author":"Trapani","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2025.116854_b0025","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/17425255.2021.1865310","article-title":"Recent advances in the personalized treatment of estrogen receptor-positive breast cancer with tamoxifen: a focus on pharmacogenomics","volume":"17","author":"Slana\u0159","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.bcp.2025.116854_b0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11154-007-9034-4","article-title":"SERMs for the treatment and prevention of breast cancer","volume":"8","author":"Swaby","year":"2007","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.bcp.2025.116854_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102375","article-title":"Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality","volume":"105","author":"Kerr","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2025.116854_b0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41416-023-02293-z","article-title":"Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women","volume":"129","author":"Hammarstr\u00f6m","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2025.116854_b0045","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3349\/ymj.2020.61.4.317","article-title":"Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen","volume":"61","author":"Lee","year":"2020","journal-title":"Yonsei Med. J."},{"issue":"4","key":"10.1016\/j.bcp.2025.116854_b0050","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.21037\/tau-20-630","article-title":"Deep vein thrombosis in a nonobstructive azoospermia male taking tamoxifen: a rare case report","volume":"9","author":"Sun","year":"2020","journal-title":"Translational Andrology and Urology"},{"issue":"12","key":"10.1016\/j.bcp.2025.116854_b0055","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1124\/dmd.112.047266","article-title":"Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein","volume":"40","author":"Sridar","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2025.116854_b0060","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.2147\/DDDT.S286409","article-title":"Volumetric Absorptive Microsampling as a New Biosampling Tool for Monitoring of Tamoxifen, Endoxifen, 4-OH Tamoxifen and N-Desmethyltamoxifen in Breast Cancer Patients","volume":"15","author":"Maggadani","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcp.2025.116854_b0065","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejmech.2017.11.056","article-title":"Ahmad, Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives","volume":"143","author":"Shagufta","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2025.116854_b0070","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1124\/jpet.104.065607","article-title":"Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6","volume":"310","author":"Desta","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2025.116854_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106303","article-title":"Design, synthesis, and metabolite identification of Tamoxifen esterase-activatable prodrugs","volume":"131","author":"Elbagoury","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2025.116854_b0080","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/clpt.2011.32","article-title":"Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes","volume":"89","author":"Madlensky","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2025.116854_b0085","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/bcp.14500","article-title":"Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles","volume":"87","author":"Thor\u00e9n","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2025.116854_b0090","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/17512433.2019.1610390","article-title":"Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen","volume":"12","author":"Sanchez-Spitman","year":"2019","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116854_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2015.01.048","article-title":"Endoxifen, the active metabolite of tamoxifen, inhibits cloned hERG potassium channels","volume":"752","author":"Chae","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"23","key":"10.1016\/j.bcp.2025.116854_b0100","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/jnci\/djg108","article-title":"Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine","volume":"95","author":"Stearns","year":"2003","journal-title":"J. Natl Cancer Inst."},{"issue":"9","key":"10.1016\/j.bcp.2025.116854_b0105","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2165\/00003495-200767090-00005","article-title":"Dihydropyridine calcium channel antagonists in the management of hypertension","volume":"67","author":"Epstein","year":"2007","journal-title":"Drugs"},{"issue":"10211","key":"10.1016\/j.bcp.2025.116854_b0110","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/S0140-6736(19)32317-7","article-title":"Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis","volume":"394","author":"Suchard","year":"2019","journal-title":"Lancet (london, England)"},{"key":"10.1016\/j.bcp.2025.116854_b0115","article-title":"Revisiting the drug interaction between tamoxifen and SSRI antidepressants","volume":"354","author":"Juurlink","year":"2016","journal-title":"BMJ (clinical Research Ed.)"},{"key":"10.1016\/j.bcp.2025.116854_b0120","unstructured":"U.F.a.D.A. (2018), Bioanalytical Method Validation Guidance for Industry, 2018. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry."},{"key":"10.1016\/j.bcp.2025.116854_b0125","unstructured":"P.W. Iversen, B. Beck, Y.F. Chen, W. Dere, V. Devanarayan, B.J. Eastwood, M.W. Farmen, S.J. Iturria, C. Montrose, R.A. Moore, J.R. Weidner, G.S. Sittampalam, HTS Assay Validation, in: S. Markossian, A. Grossman, M. Arkin, D. Auld, C. Austin, J. Baell, K. Brimacombe, T.D.Y. Chung, N.P. Coussens, J.L. Dahlin, V. Devanarayan, T.L. Foley, M. Glicksman, K. Gorshkov, J.V. Haas, M.D. Hall, S. Hoare, J. Inglese, P.W. Iversen, M. Lal-Nag, Z. Li, J.R. Manro, J. McGee, O. McManus, M. Pearson, T. Riss, P. Saradjian, G.S. Sittampalam, M. Tarselli, O.J. Trask, Jr., J.R. Weidner, M.J. Wildey, K. Wilson, M. Xia, X. Xu (Eds.), Assay Guidance Manual, Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda (MD), 2004."},{"issue":"4","key":"10.1016\/j.bcp.2025.116854_b0130","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot102269","article-title":"Bradford Assay for Determining Protein Concentration","volume":"2020","author":"Kielkopf","year":"2020","journal-title":"Cold Spring Harb Protoc"},{"key":"10.1016\/j.bcp.2025.116854_b0135","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2147\/DDDT.S160316","article-title":"Inhibitory effect of celecoxib on agomelatine metabolism in vitro and in vivo","volume":"12","author":"He","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2025.116854_b0140","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"10.1016\/j.bcp.2025.116854_b0145","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.bcp.2025.116854_b0150","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"11","key":"10.1016\/j.bcp.2025.116854_b0155","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.017","article-title":"Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023","volume":"34","author":"Curigliano","year":"2023","journal-title":"Annals of Oncology : Official Journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.bcp.2025.116854_b0160","doi-asserted-by":"crossref","unstructured":"Y. Tian, Z.H. Chen, P. Wu, D. Zhang, Y. Ma, X.F. Liu, X. Wang, D. Ding, X.C. Cao, Y. Yu, MIR497HG-Derived miR-195 and miR-497 Mediate Tamoxifen Resistance via PI3K\/AKT Signaling in Breast Cancer, Advanced science (Weinheim, Baden-Wurttemberg, Germany) 10(12) (2023) e2204819.","DOI":"10.1002\/advs.202204819"},{"issue":"10","key":"10.1016\/j.bcp.2025.116854_b0165","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022112408","article-title":"CircPVT1 promotes ER-positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS","volume":"42","author":"Yi","year":"2023","journal-title":"EMBO J."},{"issue":"8","key":"10.1016\/j.bcp.2025.116854_b0170","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1124\/dmd.30.8.869","article-title":"Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen","volume":"30","author":"Crewe","year":"2002","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"10.1016\/j.bcp.2025.116854_b0175","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00228-017-2323-2","article-title":"Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism","volume":"73","author":"Sanchez Spitman","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2025.116854_b0180","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/jcpt.13598","article-title":"Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: A systematic review and meta-analysis","volume":"47","author":"Yu","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2025.116854_b0185","first-page":"1831","article-title":"Risk of Cardiovascular Events and Lipid Profile Change in Patients with Breast Cancer Taking Aromatase Inhibitor","volume":"30","author":"Yoo","year":"2023","journal-title":"A Systematic Review and Meta-Analysis, Current Oncology (toronto, Ont.)"},{"issue":"4","key":"10.1016\/j.bcp.2025.116854_b0190","first-page":"145","article-title":"The Cardiovascular Risks Associated with Aromatase Inhibitors","volume":"25","author":"Alfaris","year":"2023","journal-title":"Tamoxifen, and GnRH Agonists in Women with Breast Cancer, Current Atherosclerosis Reports"},{"issue":"6","key":"10.1016\/j.bcp.2025.116854_b0195","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3748\/wjg.v7.i6.830","article-title":"Chiral metabolism of propafenone in rat hepatic microsomes treated with two inducers","volume":"7","author":"Zhou","year":"2001","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.bcp.2025.116854_b0200","first-page":"347","article-title":"Effect of nimodipine, a dihydropyridine calcium channel antagonist on the pharmacokinetics of carbamazepine in rhesus monkeys","volume":"47","author":"Gupta","year":"2003","journal-title":"Indian J. Physiol. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2025.116854_b0205","doi-asserted-by":"crossref","first-page":"208","DOI":"10.18433\/J3SK5V","article-title":"Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats","volume":"15","author":"Yan","year":"2012","journal-title":"Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques"},{"issue":"3","key":"10.1016\/j.bcp.2025.116854_b0210","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s13318-011-0076-3","article-title":"Different effects of dihydropyridine calcium channel antagonists on CYP3A4 enzyme of human liver microsomes","volume":"37","author":"Xia","year":"2012","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2025.116854_b0215","first-page":"74","article-title":"Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage","volume":"28","author":"R\u00e4msch","year":"1985","journal-title":"Neurochirurgia (stuttg)"},{"issue":"Suppl 4","key":"10.1016\/j.bcp.2025.116854_b0220","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1097\/00005344-198806124-00003","article-title":"Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease","volume":"12","author":"Eichelbaum","year":"1988","journal-title":"J Cardiovasc Pharmacol"},{"issue":"8","key":"10.1016\/j.bcp.2025.116854_b0225","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/j.1552-4604.1991.tb03764.x","article-title":"Pharmacokinetics of felodipine in chronic hemodialysis patients","volume":"31","author":"Buur","year":"1991","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.bcp.2025.116854_b0230","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF00558072","article-title":"Pharmacokinetics of felodipine in patients with liver disease","volume":"36","author":"Reg\u00e5rdh","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2025.116854_b0235","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2125.1989.tb05336.x","article-title":"Pharmacokinetics of felodipine in patients with impaired renal function","volume":"27","author":"Edgar","year":"1989","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2025.116854_b0240","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.346","article-title":"Coffee inhibition of CYP3A4 invitro was not translated to a grapefruit-like pharmacokinetic interaction clinically","volume":"5","author":"Dresser","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"issue":"1","key":"10.1016\/j.bcp.2025.116854_b0245","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/carcin\/20.1.153","article-title":"Alpha-hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identification and quantification in vivo and in vitro","volume":"20","author":"Boocock","year":"1999","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2025.116854_b0250","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.toxlet.2016.10.005","article-title":"Optical isomers of dihydropyridine calcium channel blockers display enantiospecific effects on the expression and enzyme activities of human xenobiotics-metabolizing cytochromes P450","volume":"262","author":"\u0160t\u011bp\u00e1nkov\u00e1","year":"2016","journal-title":"Toxicol. Lett."},{"issue":"1","key":"10.1016\/j.bcp.2025.116854_b0255","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0090-9556(25)07102-8","article-title":"Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient","volume":"19","author":"Robinson","year":"1991","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.bcp.2025.116854_b0260","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/carcin\/15.4.589","article-title":"A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes","volume":"15","author":"Lim","year":"1994","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2025.116854_b0265","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8815447","article-title":"Network Pharmacology and Molecular Docking Analysis on Molecular Targets and Mechanisms of Buyang Huanwu Decoction in the Treatment of Ischemic Stroke","volume":"2021","author":"Gao","year":"2021","journal-title":"Evid. Based Complement. Alternat. Med."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225001169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225001169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:24:50Z","timestamp":1762097090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225001169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":53,"alternative-id":["S0006295225001169"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116854","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitory effects of nimodipine, nitrendipine and felodipine on tamoxifen metabolism and molecular docking","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116854","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116854"}}